Balance Sheet
Cash Flow Statement
Asset Writedowns and ImpairmentCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in InventoryChange in ReceivablesDeferred TaxesDepreciation & Amortization (CF)Free Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeOther Working Capital ChangesShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

GeneDx Holdings (WGS) Depreciation & Amortization (CF) (2020 - 2025)

Historic Depreciation & Amortization (CF) for GeneDx Holdings (WGS) over the last 6 years, with Q3 2025 value amounting to $6.5 million.

  • GeneDx Holdings' Depreciation & Amortization (CF) rose 919.21% to $6.5 million in Q3 2025 from the same period last year, while for Sep 2025 it was $23.9 million, marking a year-over-year increase of 627.86%. This contributed to the annual value of $22.0 million for FY2024, which is 3492.32% down from last year.
  • GeneDx Holdings' Depreciation & Amortization (CF) amounted to $6.5 million in Q3 2025, which was up 919.21% from $6.2 million recorded in Q2 2025.
  • Over the past 5 years, GeneDx Holdings' Depreciation & Amortization (CF) peaked at $34.0 million during Q4 2022, and registered a low of $4.9 million during Q1 2021.
  • For the 5-year period, GeneDx Holdings' Depreciation & Amortization (CF) averaged around $8.2 million, with its median value being $5.9 million (2024).
  • In the last 5 years, GeneDx Holdings' Depreciation & Amortization (CF) soared by 48740.29% in 2022 and then tumbled by 8209.75% in 2023.
  • GeneDx Holdings' Depreciation & Amortization (CF) (Quarter) stood at $5.8 million in 2021, then surged by 487.4% to $34.0 million in 2022, then plummeted by 82.1% to $6.1 million in 2023, then fell by 8.8% to $5.6 million in 2024, then grew by 16.48% to $6.5 million in 2025.
  • Its last three reported values are $6.5 million in Q3 2025, $6.2 million for Q2 2025, and $5.7 million during Q1 2025.